Exane Derivatives’s Medifast MED Stock Holding History

Exane Derivatives’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$361	Sell	2 -522	-100%	-$93.4K	﹤0.01%	608
2022 Q1	$89.5K	Sell	524 -107	-17%	-$20.2K	0.03%	486
2021 Q4	$132K	Sell	631 -185	-23%	-$38.2K	0.03%	410
2021 Q3	$157K	Sell	816 -135	-14%	-$33.2K	0.04%	448
2021 Q2	$263K	Sell	951 -291	-23%	-$78.9K	0.06%	324
2021 Q1	$263K	Sell	1,242 -543	-30%	-$130K	0.08%	251
2020 Q4	$350K	Buy	+1,785	New	+$315K	0.1%	226

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.46B AUM 71.13% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Exane Derivatives's MED Position: Q2 2022 in Review

Exane Derivatives reduced its Medifast (MED) stake by 100% in Q2 2022, selling an estimated $93.4K and leaving 2 shares worth $361. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Exane Derivatives first reported a position in MED in Q4 2020 and has held it in 7 quarters since. The position peaked at $350K in Q4 2020. 284 funds tracked by Wall St. Rank hold MED as of Q2 2022.

Exane Derivatives held 2 shares of Medifast worth $361 as of Q2 2022.
Exane Derivatives sold 522 Medifast shares in Q2 2022, an estimated $93.4K.
Medifast made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #608 holding.
Exane Derivatives first reported a position in Medifast in Q4 2020 and has held it in 7 quarters since.
Exane Derivatives's Medifast position peaked at $350K in Q4 2020.
284 funds tracked by Wall St. Rank held Medifast as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.